Analyst Ratings For Interpace Diagnostics Group Inc (NASDAQ:IDXG)
Today, HC Wainwright set its price target on Interpace Diagnostics Group Inc (NASDAQ:IDXG) to $3.00 per share.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Interpace Diagnostics Group Inc (NASDAQ:IDXG) is Buy with a consensus target price of $3.55 per share, a potential 262.28% upside.
Some recent analyst ratings include
- 10/17/2018-Interpace Diagnostics Group Inc (NASDAQ:IDXG) has coverage initiated with a Buy rating and $4.00 price target
- 6/22/2018-Interpace Diagnostics Group Inc (NASDAQ:IDXG) has coverage initiated with a Buy rating and $2.25 price target
- 2/22/2018-Interpace Diagnostics Group Inc (NASDAQ:IDXG) has coverage initiated with a Buy ➝ Buy rating and $4.50 price target
- On 11/25/2014 Graham G Miao, CFO, bought 22,000 with an average share price of $1.65 per share and the total transaction amounting to $36,300.00.
- On 11/10/2014 Nancy Lurker, CEO, bought 49,000 with an average share price of $1.75 per share and the total transaction amounting to $85,750.00.
- On 11/7/2014 Gerald R Melillo Jr, Insider, bought 5,000 with an average share price of $1.58 per share and the total transaction amounting to $7,900.00.
- On 11/7/2014 Jeffrey Edward Smith, VP, bought 200,000 with an average share price of $1.75 per share and the total transaction amounting to $350,000.00.
- On 11/6/2014 Nancy Lurker, CEO, bought 57,000 with an average share price of $1.74 per share and the total transaction amounting to $99,180.00.
- On 11/5/2014 Gerald P Belle, Director, bought 57,300 with an average share price of $1.71 per share and the total transaction amounting to $97,983.00.
- On 11/18/2013 Gerald Belle, Director, bought 20,400 with an average share price of $5.21 per share and the total transaction amounting to $106,284.00.
About Interpace Diagnostics Group Inc (NASDAQ:IDXG)
Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Recent Trading Activity for Interpace Diagnostics Group Inc (NASDAQ:IDXG)
Shares of Interpace Diagnostics Group Inc closed the previous trading session at 0.98 −0.040 3.93% with 0.94 shares trading hands.